

Padigaru, et al.
U.S.S.N. 10/051,874

REMARKS


Applicants are filing this Amendment concurrently with a Response to the June 4, 2003 Restriction Requirement in which Applicants have elected the invention of Group II (claims 5-14, 30 and 33), drawn to a polynucleotide, vector, host cell, pharmaceutical composition and a kit. Applicants have cancelled the pending claims, and submit new claims 42-64, which are drawn to the elected invention. New claims 42-64 are fully supported by the specification and the original claims as filed. Accordingly, no new matter has been added.

Applicants also submit herewith a Petition Under 37 C.F.R. §1.48(b) along the appropriate fee under 37 C.F.R. §1.17(h) in order to delete those inventors who were correctly named in the instant application as filed, but are not inventors of the invention recited by the pending claims, as amended herein.

CONCLUSION

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and/or these remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

 Reg No. 53,097
Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No.: 30623